Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan

Physiological Genomics

Volumn 2001, Issue 4, 2001, Pages 35-42

  Wong, Victoria Y ^a   Laping, Nicholas J ^a   Contino, Lisa C ^a   Olson, Barbara A ^a   Grygielko, Eugene ^a   Brooks, David P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Plasminogen activator inhibitor 1; Renal disease; Transforming growth factor

Indexed keywords

ACRYLIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; EPROSARTAN; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HYPERTENSION; KIDNEY DISEASE; MALE; NEPHRECTOMY; PROTEINURIA; RAT; SPRAGUE DAWLEY RAT;

ACRYLATES; ANIMALS; ANTIHYPERTENSIVE AGENTS; GENE EXPRESSION REGULATION; HYPERTENSION; IMIDAZOLES; KIDNEY DISEASES; MALE; NEPHRECTOMY; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN; THIOPHENES;

EID: 0347079832     PISSN: 15312267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ali SM, Laping NJ, Fredrickson TA, Contino LC, Olson BA, Anderson K, and Brooks DP. Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease. Pharmacology 57: 20-27, 1998.
2. Anderson S, Rennke HG, and Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 7: 1993-2000, 1986.
3. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG Jr, and Feuerstein GZ. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 270: 948-955, 1996.
4. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol Renal Fluid Electrolyte Physiol 249: F324-F337, 1985.
5. Brooks DP, Fredrickson TA, Weinstock J, Ruffolo RR Jr, Edwards RM, and Gellai M. Antihypertensive activity of the nonpeptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Naunyn-Schmiedebergs Arch Pharmacol 345: 673-678, 1992.
6. Claisse D, Martiny I, Chaqour B, Wegrowski Y, Petitfrere E, Schneider C, Haye B, and Bellon G. Influence of transforming growth factor beta 1 (TGF-beta 1) on the behaviour of porcine thyroid epithelial cells in primary culture through thrombospondin-1 synthesis. J Cell Sci 112: 1405-1416, 1999.
7. Davidsohn L and Henry JB. Clinical Diagnosis by Laboratory Methods (14th ed.). Philadelphia: Saunders, 1969, p. 48.
8. Edwards RM. Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol Renal Fluid Electrolyte Physiol 244: F526-F534, 1983.
9. Edwards RM, Aiyar N, Ohlstein EH, Weidley EF, Griffin E, Ezekiel M, Keenan RM, Ruffolo RR, and Weinstock J. Pharmacological characterization of the nonpeptide angiotensin II receptor agonist, SK&F 108566. J Pharmacol Exp Ther 260: 175-181, 1992.
10. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, and Schena FP. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 56: 461-470, 1999.
11. Gibbons GH, Pratt RE, and Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 90: 456-461, 1992.
12. Go C, Li P, and Wang XJ. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res 59: 2861-2868, 1999.
13. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, and Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 43: 426-429, 1994.
14. 4-receptor system in the rat kidney. Am J Physiol Renal Physiol 274: F290-F299, 1998.
15. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, and Murakami K. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103: 627-635, 1999.
16. Ishidoya S, Morrissey J, McCracken R, Reyes A, and Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285-1294, 1995.
17. Junaid A, Rosenberg ME, and Hostetter TH. Interaction of angiotensin II and TGF-β1 in the rat remnant kidney. J Am Soc Nephrol 8: 1732-1738, 1997.
18. Kagami S, Border WA, Miller DE, and Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994.
19. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, and Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51: 664-671, 1997.
20. Kerins DM, Hao Q, and Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96: 2515-2520, 1995.
21. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, and Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273: 509-515, 1995.
22. Nakamura T, Obata J, Onizuka M, Kimura H, Ohno S, Yoshida Y, Kawachi H, and Shimizu F. Candesartan prevents the progression of mesangioproliferative nephritis in rats. Kidney Int 63: S226-S228, 1997.
23. Negoescu A, Lafeuillade B, Pellerin S, Chambaz EM, and Feige JJ. Transforming growth factors beta stimulate both thrombospondin-1 and CISP/thrombospondin-2 synthesis by bovine adrenocortical cells. Exp Cell Res 217: 404-409, 1995.
24. Noda M, Matsuo T, Fukuda R, Ohta M, Nagano H, Shibouta Y, Naka T, Nishikawa K, and Imura Y. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 56: 898-909, 1999.
25. Obata J, Nakamura T, Kuroyanagi R, Yoshida Y, Guo DF, and Inagami T. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats. Kidney Int 63: S229-S231, 1997.
26. Olson BA, Day JR, and Laping NJ. Age-related expression of renal thrombospondin 1 mRNA in F344 rats: Resemblance to diabetes-induced expression in obese Zucker rats. Pharmacology 58: 200-208, 1999.
27. I receptors on glomerular injury in Dahl salt-sensitive rats. Am J Physiol Regulatory Integrative Comp Physiol 274: R1797-R1806, 1998.
28. Ribeiro SMF, Poczatek M, Schultz-Cherry S, Villain M, and Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274: 13586-13593, 1999.
29. Roberts AM, McCune BK, and Sporn MB. Transforming growth factor β: regulation of extracellular matrix. Kidney Int 41: 557-559, 1992.
30. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, Roberts DD, and Murphy-Ullrich JE. Regulation of transforming growth factor-β activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310, 1995.
31. Shihab FS, Bennett WM, Tanner AM, and Andoh TF. Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. Kidney Int 52: 660-673, 1997.
32. Vaughan DE, Lazos SA, and Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 95: 995-1001, 1995.
33. Wang L, Eberhard M, and Erne P. Stimulation of DNA and RNA synthesis in cultured rabbit cardiac fibroblasts by angiotensin IV. Clin Sci (Colch) 88: 557-562, 1995.
34. Wang X, Yue TL, Barone FC, and Feuerstein GZ. Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex. Stroke 26: 1665-1669, 1995.
35. Wolf G, Schneider A, Wenzel U, Helmchen U, and Stahl RA. Regulation of glomerular TGF-beta expression in the contralateral kidney of two-kidney, one-clip hypertensive rats. J Am Soc Nephrol 9: 763-772, 1998.
36. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, and Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 51: 1553-1567, 1997.
37. Yayama K, Makino J, Takano M, and Okamoto H. Role of angiotensin II in the transforming growth factor-beta 1 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritis. Biol Pharm Bull 18: 687-690, 1995.
38. Yoshida Y, Kawamura T, Ikoma M, Fogo A, and Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36: 626-635, 1989.
39. Zoja C, Abbate M, Corna D, Capitanio M, Donadelli R, Bruzzi I, Oldroyd S, Benigni A, and Remuzzi G. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-β in experimental mesangioproliferative glomerulonephritis. Am J Kidney Dis 31: 453-463, 1998.